Skip to main content
Robb Friedman, MD, Oncology, South Weymouth, MA

Robb Scott Friedman MD

Hematologic Oncology


Clinical Instructor in Medicine, Harvard Medical School

Join to View Full Profile
  • Dana Farber Cancer InstituteSouth Shore HospitalSouth Weymouth, MA 02190

  • Phone+1 781-624-4800

Dr. Friedman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Tufts Medical Center
    Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
  • MedStar Health Georgetown University/Georgetown Hospital
    MedStar Health Georgetown University/Georgetown HospitalResidency, Internal Medicine, 2002 - 2004
  • Georgetown University School of Medicine
    Georgetown University School of MedicineClass of 1997

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1999 - Present
  • MA State Medical License
    MA State Medical License 2004 - 2026
  • VA State Medical License
    VA State Medical License 2002 - 2004
  • MD State Medical License
    MD State Medical License 1998 - 2000
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Hematology
    American Board of Internal Medicine Hematology
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Publications & Presentations

PubMed

Abstracts/Posters

  • Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy
    Robb S Friedman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma
    Robb S Friedman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Robb S Friedman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: